EphA2
EphA2 Informations sur la molécule
| Nom anglais | Ephrin type-A receptor 2 | Nombre de médicaments commercialisés | 2 |
| Nombre de médicaments cliniques | 9 | Alias de la cible | EC:2.7.10.1，Epithelial Cell Receptor Protein Tyrosine Kinase，Ephrin type-A receptor 2，Epithelial cell kinase，EPHA2，EPH Receptor A2，Tyrosine-Protein Kinase Receptor ECK，ECK，Soluble EPHA2 Variant 1，EC 2.7.10.1，CTRCT6，ARCC2，CTPP1，CTPA，Receptor， EphA2，EC 2.7.10 |
| Phase de R&D la plus avancée | Approved | ||
| Nom anglais | Ephrin type-A receptor 2 |
| Alias de la cible | EC:2.7.10.1，Epithelial Cell Receptor Protein Tyrosine Kinase，Ephrin type-A receptor 2，Epithelial cell kinase，EPHA2，EPH Receptor A2，Tyrosine-Protein Kinase Receptor ECK，ECK，Soluble EPHA2 Variant 1，EC 2.7.10.1，CTRCT6，ARCC2，CTPP1，CTPA，Receptor， EphA2，EC 2.7.10 |
| Nombre de médicaments commercialisés | 2 |
| Nombre de médicaments cliniques | 9 |
| Phase de R&D la plus avancée | Approved |
EphA2 Liste de produits
- Attribut
Protein (3)
- Bibliothèque de produits
En ligne (3)
- Espèces
Human (2)Rat (1)
- Étiquette
His Tag (2)His Tag & Avi Tag (1)
- Marqueur
Unconjugated (2)Biotin-labeled (1)
| Numéro de produit | Espèces | Système d'expression | Description du produit | Structure protéique | Pureté | Caractéristiques | Pré-commande/Commande |
|---|---|---|---|---|---|---|---|
 Human | HEK293 | Human EphA2 Protein, His Tag, low endotoxin (MALS verified) |  |  |  |  Ajouter au panier | |
| Human | HEK293 | Biotinylated Human EphA2 Protein, His,Avitag™ (MALS verified) |  | | | Ajouter au panier | |
 Rat | HEK293 | Rat EphA2 Protein, His Tag (MALS verified) |  | | | Ajouter au panier |
Quantité totale3
- 1
EphA2Contexte de la molécule
Receptor tyrosine kinase which binds promiscuously membrane-bound ephrin-A family ligands residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells. The signaling pathway downstream of the receptor is referred to as forward signaling while the signaling pathway downstream of the ephrin ligand is referred to as reverse signaling. Activated by the ligand ephrin-A1/EFNA1 regulates migration, integrin-mediated adhesion, proliferation and differentiation of cells. Regulates cell adhesion and differentiation through DSG1/desmoglein-1 and inhibition of the ERK1/ERK2 (MAPK3/MAPK1, respectively) signaling pathway. Engaged by the ligand ephrin-A5/EFNA5 may regulate lens fiber cells shape and interactions and be important for lens transparency development and maintenance. With ephrin-A2/EFNA2 may play a role in bone remodeling through regulation of osteoclastogenesis and osteoblastogenesis.
EphA2Alias de la molécule
EphA2
Informations sur les médicaments cliniques
| Nom anglais | Code de recherche | Phase de R&D | Entreprise | Indication | Essai clinique |
|---|---|---|---|---|---|
| BT-5528 | BT-5528; BT5528 | Phase 2 Clinical | Bicycle Therapeutics | Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Head and Neck Neoplasms; Ovarian Neoplasms; Triple Negative Breast Neoplasms | Details |
| siRNA-EphA2-DOPC | Phase 1 Clinical | The University Of Texas MD Anderson Cancer Center | Ovarian Neoplasms; Pancreatic Neoplasms; Solid tumours | Details | |
| 18F-Dasatinib | 18F-SKI-249380; [18F]-Fluoro-BMS-354825; [18F]Dasatinib; [18F]SKI-249380; [18F]Fluoro-BMS-354825 | Phase 1 Clinical | Memorial Sloan Kettering Cancer Center | Bone Marrow Neoplasms; Carcinoma; Diagnostic agents; Lymphoma; Melanoma; Neoplasms; Sarcoma | Details |
| E-Sync T Cell Therapy (University of California/National Cancer Institute/California Institute for Regenerative Medicine) | Phase 1 Clinical | University Of California San Francisco | Glioblastoma | Details | |
| SC-102 | SC-102 | Phase 1 Clinical | Tianjin Conjustar Biotechnology Co Ltd | Neoplasms; Solid tumours | Details |
| EphA2-targeted CAR-DCs therapy (Second Affiliated Hospital School Of Zhejiang University School Of Medicine) | Phase 1 Clinical | Second Affiliated Hospital School Of Zhejiang University School Of Medicine | Carcinoma, Non-Small-Cell Lung | Details | |
| EphA2-targeted CAR-T Cells therapy (Second Affiliated Hospital School Of Zhejiang University School Of Medicine) | Phase 1 Clinical | Second Affiliated Hospital School Of Zhejiang University School Of Medicine | Carcinoma, Non-Small-Cell Lung | Details | |
| Autologous Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13R alpha2 CAR (E-SYNC) T Cells therapy(California Institute For Regenerative Medicine) | Phase 1 Clinical | California Institute For Regenerative Medicine, National Cancer Institute | Glioblastoma | Details | |
| [18F]AlF-ETN | [18F]AlF-ETN | Phase 1 Clinical | Capital Medical University, Yunnan Baiyao Group Co Ltd | Prostatic Neoplasms; Solid tumours | Details |
Informations sur les médicaments commercialisés
| Nom anglais | Code de recherche | Phase de R&D | Entreprise | Plus ancien nom de marque | Pays d'approbation le plus ancien | Indication la plus ancienne | Société d'approbation la plus ancienne | Date d'approbation la plus ancienne | Indication | Essai clinique |
|---|---|---|---|---|---|---|---|---|---|---|
| Regorafenib | DAST; BAY-73-4506 | Approved | Bayer AG | Stivarga, Resihance | United States | Colorectal Neoplasms | Bayer Healthcare Pharmaceuticals Inc | 2012-09-27 | Adenocarcinoma; Adenoma; Bile Duct Neoplasms; Carcinoma, Adenoid Cystic; Carcinoma, Hepatocellular; Carcinoma, Islet Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Colonic Neoplasms; Colorectal Neoplasms; Esophageal adenocarcinoma; Esophageal Neoplasms; Fallopian Tube Neoplasms; Gastrinoma; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Glucagonoma; Hemangiosarcoma; Insulinoma; Leukemia, Myeloid, Acute; Liver Neoplasms; Lung Neoplasms; Melanoma; Meningioma; Neoplasm Metastasis; Neoplasms; Osteosarcoma; Ovarian Neoplasms; Pancreatic Neoplasms; Peritoneal Neoplasms; Rectal Neoplasms; Sarcoma; Sarcoma, Ewing; Solid tumours; Somatostatinoma; Stomach Neoplasms; Thymoma; Thyroid Neoplasms | Details |
| Dasatinib Hydrate | NSC-732517; BMS-354825 | Approved | Bristol-Myers Squibb Company | Spraysel, 施达赛, Spricel, Sprycel | United States | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myelogenous, Chronic | Bristol-Myers Squibb Company | 2006-06-28 | Adenocarcinoma, Clear Cell; Angioimmunoblastic T-cell Lymphoma; Astrocytoma; Blast Crisis; Bone metastases; Brain Neoplasms; Breast Neoplasms; Burkitt Lymphoma; Carcinoma, Basosquamous; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Carcinoma, Verrucous; Cholangiocarcinoma; Chondrosarcoma; Chordoma; Colonic Neoplasms; Coronavirus Disease 2019 (COVID-19); Cystadenocarcinoma; Endometrial Neoplasms; Fallopian Tube Neoplasms; Gastrointestinal Stromal Tumors; Giant Cell Tumor of Bone; Glioblastoma; Glioma; Gliosarcoma; Heart Arrest; Hemangiopericytoma; Hematologic Neoplasms; HIV Infections; Hodgkin Disease; Hormone-Resistant Prostate Neoplasms; Hypereosinophilic Syndrome; Hypopharyngeal Neoplasms; Idiopathic Pulmonary Fibrosis; Immunoproliferative Small Intestinal Disease; Intraocular Lymphoma; Laryngeal Diseases; Laryngeal Neoplasms; Leukemia; Leukemia, Hairy Cell; Leukemia, Large Granular Lymphocytic; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Lymphoid; Leukemia, Myel | Details |
- Informations sur la molécule
- Liste de produits
- Informations sur les médicaments commercialisés
- Informations sur les médicaments cliniques